Cypherpunk Q2 Net Profit Surges 336% to $39.4M Driven by ZEC Gains

Cypherpunk Technologies reports Q2 2026 net profit of $39.39M, reversing a prior-year loss. The turnaround is primarily attributed to $46M in unrealized gains from ZEC holdings.

Woofun AI reports that Cypherpunk Technologies posted a net profit of $39.39 million for the second quarter of 2026, marking a sharp reversal from the $16.64 million net loss recorded in the same period last year. Diluted earnings per share stood at $0.18, while operating losses amounted to $4.69 million. Research and development expenses fell significantly to $200,000 from $10.54 million in the prior year, largely due to the completion of clinical trials. General and administrative expenses rose to $4.49 million, an increase of $2.75 million, driven by higher stock-based incentives. As of June 30, the company held a cash balance of $7.6 million.

The profitability surge was primarily fueled by a $46 million non-cash unrealized gain on ZEC holdings, as the token price climbed from $243.35 to $400.09 during the quarter. As of August 11, 2026, the firm held 323,394.38 ZEC coins with an average cost basis of approximately $341.83, representing about 1.92% of the total circulating supply and a market value of roughly $129 million. In business developments, the company appointed Dev Ojha, founder of Valar Group, as an advisor.

Additionally, its subsidiary Leap Therapeutics reached an agreement with the U.S. FDA regarding Phase III clinical trial design for sirexatamab, which received Fast Track status in May 2026 for treating stage II metastatic colorectal cancer.